Vir Biotechnology Inc (NASDAQ: VIR) on Tuesday, soared 6.59% from the previous trading day, before settling in for the closing price of $5.92. Within the past 52 weeks, VIR’s price has moved between $4.16 and $12.03.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -18.74%. The company achieved an average annual earnings per share of 12.46%. With a float of $94.05 million, this company’s outstanding shares have now reached $139.02 million.
Vir Biotechnology Inc (VIR) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Vir Biotechnology Inc is 32.40%, while institutional ownership is 54.17%. The most recent insider transaction that took place on Jan 02 ’26, was worth 130,383. In this transaction Director of this company sold 22,000 shares at a rate of $5.93, taking the stock ownership to the 1,166,391 shares. Before that another transaction happened on Jan 02 ’26, when Company’s Director proposed sale 66,000 for $6.03, making the entire transaction worth $397,980.
Vir Biotechnology Inc (VIR) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.76 earnings per share (EPS) for the period topping the consensus outlook (set at -0.87) by 0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.6 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.46% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.39% during the next five years compared to -18.74% drop over the previous five years of trading.
Vir Biotechnology Inc (NASDAQ: VIR) Trading Performance Indicators
Vir Biotechnology Inc (VIR) is currently performing well based on its current performance indicators. A quick ratio of 7.25 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 52.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.62, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -2.93 in one year’s time.
